Aktuelles zu Bewährtem und neue Optionen in der Therapie

M. Marziniak

doi:10.1055/s-0038-1627758

Nervenheilkunde, Table of Contents

Nervenheilkunde 2014; 33(12): 905-910
DOI: 10.1055/s-0038-1627758

Multiple Sklerose

Schattauer GmbH

Aktuelles zu Bewährtem und neue Optionen in der Therapie

Multiple sclerosis – new therapeutic options and news about the long-standing drugs

Authors

M. Marziniak

¹Klinik für Neurologie und Zentrum für Neurologische Intensivmedizin, Isar-Amper-Klinikum, München-Ost, Haar

Abstract

Zusammenfassung

Die in den vergangenen 12 Monaten in Deutschland zugelassenen vier Medikamente zur Behandlung der schubförmigen Form der Multiplen Sklerose (Alemtuzumab, pegyliertes Betainterferon, Dimethylfumarat, Teriflunomid) werden ausführlich vorgestellt. Zusätzlich wird ein kurzer Überblick über die neuen Erkenntnisse der bewährten MS-Therapeutika gegeben. Neben der medizinischen Nutzen-Risiko-Abwägung, die insbesondere für die drei Therapeutika der Behandlung der (hoch)aktiven Form: Alemtuzumab, Fingolimod, Natalizumab gilt, werden die individuelle Patientensituation (Schwangerschaftswunsch, Compliance von Nachkontrollen) und die Applikationsform als wichtiges Entscheidungsmerkmal der Patienten diskutiert.

Summary

Four new drugs (alemtuzumab, pegylated betainterferon, dimethylfumarate, teriflunomid) were available in the treatment of relapsingremitting multiple sclerosis within the last 12 months in Germany. These drugs were discussed in detail. Additionally there is a short overview about the new insides of the well known MS drugs. The benefit-risk ratio, that is important especially for the three treatment options (alemtuzmab, fingolimod, natalizumab) of the highly active multiple sclerosis, the individual situation of the patient (planned pregnancy, compliance of redundant safety visits), and the kind of application are presented as important reasons for the therapeutic decision of the patient.

Schlüsselwörter

Multiple Sklerose - neue Therapien - Alemtuzumab - Betainterferone - Dimethylfumarat - Fingolimod - Natalizumab - Teriflunomid

Keywords

Multiple sclerosis - new therapies - alemtuzumab - dimethylfumarate - fingolimod - natalizumab - teriflunomid

Full Text

References

Literatur
1 Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (02) 292-302.
2 Marziniak M, Meuth SG. Current perspectives on interferon beta-1b for the treatment of multiple sclerosis. Adv Ther. 2014 Sep 3; E-pub ahead of print
3 www.bfarm.de/SharedDocs/Risikoinformationen/ Pharmakovigilanz/DE/RHB/2014/info-interferonbeta.pdf?_blob=publicationFile&v=2
4 Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddigzadeh A, Hung S, Deykin A. ADVANCE Study Investigators. Pegylated interferon alpha-1a for relapsingremitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13 (07) 657-65.
5 Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73 (06) 705-13.
6 van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 2011; 1812: 141-50.
7 Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-5.
8 Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, van Dam AB. Detocification enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005; 166: 132-43.
9 Zoghi S, Amirghofran Z, Nikseresht A, Ashjazadeh N, Kamali-Sarvestani E, Rezaei N. Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients with fumaric acid esters. Immunol Invest 2011; 40 (06) 581-96.
10 Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005; 11 (01) 43-8.
11 Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368 (17) 1657-8.
12 van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368 (17) 1658-9.
13 Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367 (12) 1098-107.
14 Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT. CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367 (12) 1087-97.
15 Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 2010; 124: 75-84.
16 Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012; 142 (01) 49-6.
17 O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS. TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365 (14) 1293-303.
18 Kappos L, Comi G, Confavreux C. et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a Phase III placebo-controlled study. Conference paper. European Committee for treatment and research in MS. ECTRIMS. 2013. Lyon, Frankreich.:
19 Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O’Connor P. TENERE Trial Group. for the Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014; 20 (06) 705-16.
20 Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35 (11) 3332-42.
21 Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
22 Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004; 106 (03) 270-4.
23 Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856): 1819-28.
24 Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. 380 (9856) 1829-39.
25 Hiestand PC, Rausch M, Meier DP. et al. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. Prog Drug Res 2008; 66 (361) 363-81.
26 Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29: 558-65.
27 Coelho RP, Payne SG, Bittman R. et al. The immunomodulatorFTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323: 626-35.
28 Mullershausen F, Craveiro LM, Shin Y. et al. Phosphorylated FTY720 promotes astrocyte migration through shingosine 1 phosphatereceptors. J Neurochem 2007; 102: 1151-61.
29 Miron VE, Jung CG, Kim HJ. et al. FTY720 modulates human oligodnedrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61-71.
30 Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
31 Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-40.
32 www.bfarm.de/SharedDocs/Risikoinformationen/DE/RHB/2013/rhb-gilenya4.html
33 www.dgn.org/component/content/article/45-leitlinien-der-dgn-2012/2333-ll-31–2012-diagnose-und-therapie-der-multiplen-skle-rose.html?q=multiple+sklerose
34 Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-6.
35 Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 (09) 899-910.
36 Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
37 Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M. Anti-JC virus anti-bodies: implications for PML risk stratification. Ann Neurol 2010; 68 (03) 295-303.